As filed with the Securities and Exchange Commission on March 29, 2024
Registration No. 333-
___________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________
___________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________________________________________________________________________________
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
________________________________________________________________________________________
AN2 Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
________________________________________________________________________________________
|
|
|
Delaware |
| 82-0606654 |
(State or other jurisdiction of |
| (I.R.S. Employer |
1800 El Camino Real, Suite D
Menlo Park, California 94027
(Address of principal executive offices) (Zip code)
AN2 Therapeutics, Inc. 2022 Equity Incentive Plan
AN2 Therapeutics, Inc. 2022 Employee Stock Purchase Plan
(Full titles of the plans)
Eric Easom
Chief Executive Officer
AN2 Therapeutics, Inc.
1800 El Camino Real, Suite D
Menlo Park, California 94027
(650) 331-9090
(Name and address of agent for service) (Telephone number, including area code, of agent for service)
________________________________________________________________________________________
Copies to:
|
|
|
Kathleen M. Wells |
| Lucy O. Day AN2 Therapeutics, Inc. Menlo Park, California 94027 (650) 331-9090 |
________________________________________________________________________________________
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
|
|
|
|
|
|
|
Large accelerated filer |
| ☐ |
| Accelerated filer |
| ☐ |
|
|
|
| |||
Non-accelerated filer |
| ☒ |
| Smaller reporting company |
| ☒ |
|
|
|
| |||
|
|
|
| Emerging growth company |
| ☒ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
___________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________
___________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________
EXPLANATORY NOTE
REGISTRATION OF ADDITIONAL SHARES
Pursuant to General Instruction E of Form S-8, AN2 Therapeutics, Inc. (the “Registrant”) is filing this Registration Statement on Form S-8 with the Securities and Exchange Commission (the “Commission”) for the purpose of registering (i) 1,189,657 additional shares of its Common Stock, par value $0.00001 per share (“Common Stock”), under the 2022 Equity Incentive Plan (the “2022 Plan”), pursuant to the provisions of the 2022 Plan providing for an automatic increase in the number of shares of Common Stock reserved and available for issuance under the 2022 Plan on January 1, 2024, and (ii) 297,414 additional shares of its Common Stock under the 2022 Employee Stock Purchase Plan (the “2022 ESPP,” together with the 2022 Plan, the “Plans”), pursuant to the provisions of the 2022 ESPP providing for an automatic increase in the number of shares of Common Stock reserved and available for issuance under the 2022 ESPP on January 1, 2024. In accordance with the instructional note to Part I of Form S-8 as promulgated by the Commission, the information specified by Part I of the Form S-8 has been omitted from this Registration Statement.
The Registrant previously registered shares of its Common Stock for issuance under the Plans on a Registration Statement on Form S-8 filed with the Commission on March 29, 2022 (File No. 333-263917) and a Registration Statement on Form S-8 filed with the Commission on March 30, 2023 (File No. 333-270962). Pursuant to General Instruction E to Form S-8, this Registration Statement hereby incorporates by reference the contents of the Registration Statements referenced above except as set forth below.
PART II
INFORMATION REQUIRED IN REGISTRATION STATEMENT
ITEM 3. INCORPORATION OF DOCUMENTS BY REFERENCE
The following documents filed by the Registrant with the Commission are incorporated by reference into this Registration Statement:
(a) The Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the Commission on March 29, 2024.
(b) The Registrant’s Current Report on Form 8-K, filed with the Commission on February 12, 2024.
(c) The description of the Registrant’s Common Stock which is contained in the Registrant’s Registration Statement on Form 8-A filed on March 22, 2022 (File No. 001-41331) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), as updated by Exhibit 4.3 to the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, filed with the Commission on March 29, 2023, including any amendment or report filed for the purpose of updating such description.
(d) All other reports and documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14, and 15(d) of the Exchange Act (other than Current Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items) on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part of this Registration Statement from the date of the filing of such reports and documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document that also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.
ITEM 8. EXHIBITS
Incorporated by Reference | ||||||||||
Exhibit Number | Description | Form | File No. | Exhibit | Filing Date | |||||
4.1 | Amended and Restated Certificate of Incorporation of the Registrant. | S-1 | 333-263295 | 3.2 | March 4 2022 | |||||
4.2 | S-1 | 333-263295 | 3.4 | March 4, 2022 | ||||||
4.3 |
|
| S-1 |
| 333-263295 |
| 4.1 |
| March 21, 2022 | |
5.1* |
|
|
|
|
|
|
|
|
| |
23.1* |
|
|
|
|
|
|
|
|
| |
23.2* |
|
|
|
|
|
|
|
|
| |
24.1* |
| Power of Attorney (included on the signature page of this Registration Statement). |
|
|
|
|
|
|
|
|
99.1# |
|
| 10-K |
| 001-41331 |
| 10.3 |
| March 29, 2024 | |
99.2# |
|
| S-1 |
| 333-263295 |
| 10.4 |
| March 4, 2022 | |
99.3# |
|
| 10-K |
| 001-41331 |
| 10.5 |
| March 29, 2024 | |
99.4# |
|
| 10-K |
| 001-41331 |
| 10.6 |
| March 29, 2024 | |
107.1* |
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
* Filed herewith.
# Indicates management contract or compensatory plan.
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Menlo Park, State of California, on March 29, 2024.
|
|
|
AN2 THERAPEUTICS, INC. | ||
|
| |
By: |
| /s/ Eric Easom |
|
| Eric Easom |
|
| President and Chief Executive Officer |
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Eric Easom and Lucy O. Day, and each of them, as his or her true and lawful attorneys-in-fact and agents, each with the full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this Registration Statement (including post-effective amendments), and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed below by the following persons in the capacities and on the dates indicated.
Signature |
| Title |
| Date |
|
|
|
|
|
/s/ Eric Easom |
| Chief Executive Officer and Director |
| March 29, 2024 |
Eric Easom |
|
|
|
|
|
|
|
|
|
/s/ Lucy O. Day |
| Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) |
| March 29, 2024 |
Lucy O. Day |
|
|
|
|
|
|
|
|
|
/s/ Joseph Zakrzewski |
| Board Chair and Director |
| March 29, 2024 |
Joseph Zakrzewski |
|
|
|
|
|
|
|
|
|
/s/ Kabeer Aziz |
| Director |
| March 29, 2024 |
Kabeer Aziz |
|
|
|
|
|
|
|
|
|
/s/ Maggie FitzPatrick |
| Director |
| March 29, 2024 |
Maggie FItzPatrick |
|
|
|
|
|
|
|
|
|
/s/ Gilbert L. Marks |
| Director |
| March 29, 2024 |
Gilbert L. Marks |
|
|
|
|
|
|
|
|
|
/s/ Patricia (Patty) Martin |
| Director |
| March 29, 2024 |
Patricia (Patty) Martin |
|
|
|
|
|
|
|
|
|
/s/ Rob Readnour |
| Director |
| March 29, 2024 |
Rob Readnour |
|
|
|
|
|
|
|
|
|
/s/ Melvin Spigelman |
| Director |
| March 29, 2024 |
Melvin Spigelman |
|
|
|
|
|
|
|
|
|
/s/ Stephanie Wong |
| Director |
| March 29, 2024 |
Stephanie Wong |
|
|
|
|
